Introduction
Thymidylate synthase (TS) is a critical enzyme in the de novo biosynthesis of thymidine-5 0 -monophosphate (dTMP) and therefore essential for DNA synthesis. TS catalyzes the reductive methylation of 2 0 -deoxyuridine-5 0 -monophosphate (dUMP) to yield dTMP using 5,10-methylene tetrahydrofolate as a cofactor. 1 Since TS is an essential enzyme in proliferating cells and its increased expression, resulting from loss of tumor suppressor function, is common in cancer, [2] [3] [4] this enzyme has for many years been an important target in cancer chemotherapy.
The fluoropyrimidine, 5-fluorouracil (5-FU), and the quinazoline antifolate, Tomudex (TDX), are wellknown examples of TS inhibitors. 5-FU is currently the most widely used drug for the treatment of colon cancer. 5 A common problem arising from the use of these TS inhibitors is the development of resistant tumor cells, which display increased intracellular TS expression due to gene amplification. [6] [7] [8] Intratumoral TS gene expression correlates with the lack of clinical response to fluoropyrimidines and with poor clinical prognosis in several cancers. [9] [10] [11] To circumvent this problem of drug-induced resistance, we developed a novel approach called enzyme catalyzed therapeutic activation (ECTA). TS ECTA takes advantage of the overexpression of TS in tumor cells. The TS ECTA compound, NB1011, is a nucleotide analog phosphoramidate, (E)-5-(2-bromovinyl)-2 0 -deoxy-5 0 -uridyl phenyl L-alaninyl phosphoramidate, which upon entry into cells is converted to bromovinyldeoxyuridine monophosphate (BVdUMP). 12 Subsequently, during an enzymatic reaction catalyzed by TS, BVdUMP is converted into the proposed cytotoxic product(s). 12 Therefore, a high intracellular TS activity increases the sensitivity of a cell to NB1011 cytotoxicity. This differentiates NB1011 from classical TS inhibitors because NB1011
Correspondence to STC Neuteboom, NewBiotics, Inc,11760 E Sorrento Valley Road, San Diego, CA 92121, USA. Tel: (+1) 858 259-8600; Fax: (+1) 858 259-8645; E-mail: sneuteboom@newbiotics.com requires TS activity to become maximally cytotoxic. Our previous work showed that NB1011 is preferentially cytotoxic to tumor cells displaying elevated TS levels as compared to normal cells with lower levels of TS. 13 Furthermore, NB1011 exhibited antitumor activity in colon and breast carcinoma xenografts in athymic mice. 12 Because very few anticancer compounds are optimally efficacious as single agents, we sought to determine whether the in vitro cytotoxic activity of NB1011 could be enhanced using subclasses of chemotherapeutic agents with well-characterized mechanisms of action. Nucleoside transport inhibitors were of particular interest since dipyridamole has been reported to enhance the cytotoxicity of various chemotherapeutic agents including 5-FU. 14 
Materials and methods

Cell lines and cell culture
Normal human colon epithelial cells (CCD18co) and skin fibroblasts (Det551) were purchased from ATCC (Rockville, MD). H630R10, a colon carcinoma cell line resistant to 10 mM 5-FU, 6 and MCF7TDX, a breast adenocarcinoma cell line resistant to 2 mM TDX, 15 served as models for high TS expressing human cancer cells. Both tumor cell lines express approximately 20-fold more TS protein than normal CCD18co and Det551 cells. 13 All cells were cultured under conditions of 371C, 95% humidified air, 5% CO 2 in RPMI 1640 culture medium containing 10% fetal bovine serum (FBS) or 10% dialyzed FBS (Life Technologies, Carlsbad, CA) and penicillin/streptomycin/fungizone (Life Technologies). MCF7TDX cells were maintained continuously in 2 mM TDX and H630R10 cells were maintained continuously in 10 mM 5-FU. Normal cells were passaged a maximum of 15 times to avoid senescence.
Chemical reagents
Thirteen chemotherapeutic agents representative of 10 different mechanistic classes ( 
Cytotoxicity studies
AlamarBlue assay. Cells (500/well) were transferred to a 384-well tissue culture plate (Corning, Corning, NY) and allowed to attach for 24 h. Compounds were then applied in an orthogonal pattern as described. 16 Following a 5-day incubation, the redox indicator dye, alamarBlue (AccuMed International, Westlake, OH) was added to each well at a 10% (v/v) ratio, and fluorescence was monitored at 535 nm excitation and 595 nm emission.
Crystal violet assay. Exponentially growing cells were transferred at a density of approximately 5000 cells/well to a 96-well tissue culture plate and allowed to attach for 24 h. Compounds were then applied simultaneously in duplicate serial dilutions. Etoposide, dipyridamole and NBMPR were diluted from DMSO stocks to final concentrations no greater than 0.6% DMSO, which was shown in previous experiments to have no effect on cell proliferation. Each compound was tested separately and mixed together at a single molar ratio approximately equal to the ratio of the individual IC 50 values. After an additional 72-h incubation, cells were washed once with PBS and stained with 0.5% crystal violet in methanol. Plates were washed gently in water to remove unbound stain and allowed to dry overnight. Crystal violet stain bound to the total protein of attached cells was redissolved in Sorenson's buffer (0.025 M sodium citrate/0.025 M citric acid in 50% ethanol) and absorbence monitored at 535 nM. 17 Each drug combination was tested in duplicate in at least three separate assays.
Calculation of drug interactions
Cytotoxic effect levels and drug interactions were assessed by the combination index method 16, 18 using the CalcuSyn software from Biosoft (Ferguson, MO). Briefly, the IC 50 and the slope parameter (m) for each agent alone were determined from the median-effect plot, an x,y plot of log(D) versus log ( f a /f u ) based on Chou's median-effect equation:
where D is the dose of the drug, D m is the IC 50 as determined from the x-intercept of the median-effect plot, f a is the fraction of cells affected, f u is the fraction of cells unaffected ( f u =1Àf a ) and m is an exponent signifying the steepness of the sigmoid dose-effect curve. Only experiments with linear correlation coefficients (r)40.9 were accepted for analysis. A combination index (CI) was then calculated to assess synergism or antagonism according to the following equation which assumes an independent mechanism of drug action (mutual exclusivity):
where ( 
Results
Multiple drug-e¡ect analysis of NB1011in combination with chemotherapy drugs in vitro
Various anti-tumor agents from different mechanistic classes were analyzed in combination with NB1011 to identify those that enhance the anti-proliferative activity against tumor cells. The median-effect/combination index method by Chou and Talalay 16 was used to calculate CI values. CI values 41 indicate synergy, CI=1 indicates additivity and CIo1 indicates antagonism. 16, 19 A representative example using the median-effect combination index method is shown for the combination of vinblastine and NB1011 using H630R10 tumor cells (Table 1) . CI values were calculated for various dose-effect levels spanning from 10 to 60% inhibition of cell proliferation using parameters derived from dose-response curves constructed for vinblastine alone, NB1011 alone or the combination at a fixed molar ratio (see Materials and methods for details). Table 1 shows that the CI values for the combination of NB1011 and vinblastine are o1 across a broad range of doseeffect levels, indicating a synergistic interaction. Table 2 shows a summary of the data from the same analysis applied to all 13 anti-tumor agents tested in combination with NB1011 using H630R10 and MCF7TDX tumor cells. The indicated CI value for a given drug/NB1011 combination is the mean CI value calculated from several dose-effect levels.
Of the 13 agents tested, dipyridamole and NBMPR showed synergy (CIo1.0) with NB1011 against both MCF7TDX and H630R10 tumor cells (Table 2) . Vinblastine synergized with NB1011 against the H630R10 cells. Two of the remaining nine agents, irinotecan and taxol, showed an additive or antagonistic interaction (CI=1À1.4) with NB1011, while all the other agents showed antagonism (CI41.5). The most antagonistic interaction was observed with 5-FU which gave CI=3.19 against MCF7TDX cells (Table 2 ). This antagonism is expected given the TSdependent conversion of NB1011 to its cytotoxic product. In light of these results, vinblastine, dipyridamole and NBMPR were chosen for further study.
Potentiation of the cytotoxicity of NB1011by nucleoside transport inhibitors is selective for tumor cells
We determined whether the synergy with NB1011 was specific for tumor cells by evaluating the same drug combinations in the two normal cell strains, Det551 and CCD18co. Results of these experiments are shown in Table 3 . Consistent with the data shown in Table 2 , vinblastine synergized with NB1011 only against the H630R10 tumor cells (CI=0.54) ( Table  3) dipyridamole and NBMPR, which are both inhibitors of equilibrative nucleoside transport, potentiate the cytotoxic activity of NB1011. This enhancement of NB1011 cytotoxicity by dipyridamole and NBMPR appears specific for the tumor cells, since no synergy was observed for these combinations against the two normal cell types analyzed.
Synergy between NB1011and dipyridamole persists in cell culture medium depleted of nucleosides and nucleobases
Dipyridamole potentiates the cytotoxicity of various chemotherapeutic drugs including PALA, MTA, 5-FU and TDX. 14, [21] [22] [23] The mechanism of potentiation is thought to relate to the ability of dipyridamole to block the uptake and therefore salvage of pyrimidines. However additional non-salvage-dependent mechanisms have been suggested. 23, 24 In addition to blocking the influx of nucleosides and nucleobases, dipyridamole has been reported to also inhibit the efflux of deoxyuridine, thereby enhancing the intracellular accumulation of deoxyuridine nucleotides. 14, 24 One way to distinguish between dipyridamole's potentiating the cytotoxic activity of NB1011 by inhibition of nucleoside influx versus efflux is to analyze MCF7TDX cells growing in medium supplemented with fetal bovine serum (FBS) or with dialyzed FBS which is free of salvage pathway pyrimidines. If dipyridamole works by affecting pyrimidine uptake, its effects should be specific for the standard serum. Results from these experiments are shown in Table 4 . Synergy was observed between NB1011 and dipyridamole at similar levels in experiments using medium supplemented with either FBS or dialyzed FBS. These results suggest that the mechanism by which dipyridamole potentiates the cytotoxicity of NB1011 against MCF7TDX cells does not involve salvage, and may instead involve intracellular accumulation of a toxic product of NB1011 generated by TS.
Discussion
In this study we set out to employ a mechanismbased screen for chemotherapeutic drugs that would enhance the anti-proliferative activity of NB1011 against tumor cells. Our results show that of the 13 compounds tested, the only ones that were effective were the nucleoside transport inhibitors, dipyridamole and NBMPR. Furthermore, potentiation occurred selectively in tumor cell lines expressing high TS levels. Importantly, these agents did not show synergy with NB1011 when tested in the two normal cell types, suggesting the potential One of the mechanisms by which dipyridamole potentiates the activity of these antitumor agents is by inhibiting the uptake of nucleosides like uridine and thymidine, thereby blocking salvage pathways. 21, 27 However, dipyridamole has been shown to still synergize with various drugs in experiments using dialyzed serum, which limits the availability of exogenous nucleosides such as thymidine. 14, 23 This suggests the existence of other non-salvage dependent mechanisms. Indeed dipyridamole has, apart from inhibiting nucleoside influx, been reported to block the efflux of nucleosides like deoxyuridine 24 and nucleoside analogs such as fluorodeoxyuridine. 14 The detailed mechanism by which dipyridamole specifically sensitizes tumor cells to NB1011 requires further study. However, the finding that this synergy persists in dialyzed serum (lacking salvage pathway nucleosides) suggests an efflux blockade with a resulting accumulation of toxic metabolites of NB1011.
Although dipyridamole acts to sensitize tumor cells to several antitumor drugs in vitro, its clinical application for this purpose has met with limited success. 31, 32 Clinically achievable serum concentrations of dipyridamole are limited due to extensive binding to the serum protein, a 1 acid glycoprotein. 33 Depending upon the mode of delivery, a broad range of free dipyridamole concentrations has been reported: by oral dosing (450 mg in six equal doses daily), peak free dipyridamole concentrations in the serum were 24.1 nM on average; by continuous i.v. infusion, steady-state free dipyridamole concentrations were observed at an average of 27.8 nM; 32 and by local infusion, specifically i.p. infusion, higher steady-state free dipyridamole i.p. concentrations above 25 mM have been attained. 34, 35 In our in vitro combination cytotoxicity experiments potentiation of NB1011 was observed at dipyridamole concentrations ranging from 5.5 to 75 mM (Table 3) . Since protein binding in the cell culture medium (supplemented with 10% FBS) is minimal (below 25%), 36 the dipyridamole concentrations used in our experiments reflect free dipyridamole levels. Therefore, a minimum concentration of approximately 5 mM steady-state free dipyridamole would likely be required to bring about potentiation of NB1011 by dipyridamole in patients. This level is achievable by local infusion, which may represent a practical means of delivering dipyridamole in a clinically efficacious form for combination with NB1011. Additionally, recent studies have shown that dipyridamole analogs with reduced serum protein binding can effectively potentiate the cytotoxic activity of various anticancer agents such as CB3717, nolatrexed and 5-FU. 37 These new analogs of dipyridamole may be promising alternatives to overcome the difficulties in achieving effective dose levels which have limited the clinical application of dipyridamole.
Our results show that inhibition of nucleoside transporter function can dramatically increase the sensitivity of high TS-expressing tumor cells to the cytotoxic effects of NB1011. Remarkably, this synergy is observed only with the tested tumor cells and not with the normal cells we have examined. While others have noted enhanced activity of modified nucleosides in the presence of dipyridamole, 14, 26 the synergistic activity reported with NB1011 has not been observed previously. This especially applies to the lack of synergistic toxicity on normal cells which have low TS levels. These results support the novel mechanism of action of NB1011 as a nucleotide substrate of TS, as opposed to the classical inhibitors of TS function now in clinical use.
